Abstract
BackgroundThe EULAR and ACR guidelines do not recommend any biological treatment above another in terms of efficacy. Thus financial aspects, such as the real associated cost, should be taken into...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
